Jason Lohmueller

Dr. Jason Lohmueller


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2007 in Nature
Verified
Journal Article
Closed access
PDF file
TCThe International HapMap Consortium
The International HapMap Consortium
PSPardis C. Sabeti
Pardis C. Sabeti
PVPatrick Varilly
Patrick Varilly
BFBen Fry
Ben Fry
JLJason Lohmueller
Jason Lohmueller
ELEric S. Lander
Eric S. Lander

1 February 2013 in Cell
Verified
Journal Article
Closed access
YKYana G. Kamberov
Yana G. Kamberov
SWSijia Wang
Sijia Wang
JTJingze Tan
Jingze Tan
PGPascale Gerbault
Pascale Gerbault
AWAbigail Wark
Abigail Wark
PSPardis C Sabeti
Pardis C Sabeti

17 January 2014 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
FLFlorian Lienert
Florian Lienert
JLJason Lohmueller
Jason Lohmueller
AGAbhishek Garg
Abhishek Garg
PSPamela A. Silver
Pamela A. Silver

11 May 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
AGAbhishek Garg
Abhishek Garg
JLJason Lohmueller
Jason Lohmueller
PSPamela A. Silver
Pamela A. Silver
TAThomas Z. Armel
Thomas Z. Armel
The ability to engineer biological circuits that process and respond to complex cellular signals has the potential to impact many areas of biology and medicine. Transcriptional activator-like effectors (TALEs) have emerged as an attractive component for engineering these circuits, as TALEs can be designed de novo to target a given DNA sequence. Currently, however, the use of TALEs is limited by degeneracy in the site-specific manner by which they recognize DNA. Here, we propose an algorithm to computationally address this problem. We apply our algorithm to design 180 TALEs targeting 20 bp cognate binding sites that are at least 3 nt mismatches away from all 20 bp sequences in putative 2 kb human promoter regions. We generated eight of these synthetic TALE activators and showed that each is able to activate transcription from a targeted reporter. Importantly, we show that these proteins do not activate synthetic reporters containing mismatches similar to those present in the genome nor a set of endogenous genes predicted to be the most likely targets in vivo. Finally, we generated and characterized TALE repressors comprised of our orthogonal DNA binding domains and further combined them with shRNAs to accomplish near complete repression of target gene expression.

21 September 2017 in OncoImmunology
Verified
Journal Article
Open access
JLJason Lohmueller
Jason Lohmueller
JHJames D. Ham
James D. Ham
MKMichael Kvorjak
Michael Kvorjak
OFOlivera Finn
Olivera Finn
Chimeric antigen receptor T cells (CAR-Ts) are promising cancer therapeutics. However, since cancer cells can lose the CAR-targeted antigen and avoid destruction, targeting multiple antigens with multiple CARs has been proposed. We illustrate here a less cumbersome alternative, anti-tag CARs (AT-CARs) that bind to tags on tumor-targeting antibodies. We have created novel AT-CARs, using the affinity-enhanced monomeric streptavidin 2 (mSA2) biotin-binding domain that when expressed on T cells can target cancer cells coated with biotinylated antibodies. Human T cells expressing mSA2 CARs with CD28-CD3ζ and 4–1BB-CD3ζ signaling domains were activated by plate-immobilized biotin and by tumor cells coated with biotinylated antibodies against the tumor-associated antigens CD19 and CD20. Furthermore, mSA2 CAR T cells were capable of mediating cancer cell lysis and IFNγ production in an antibody dose-dependent manner. The mSA2 CAR is a universal AT-CAR that can be combined with biotinylated tumor-specific antibodies to potentially target many different tumor types.

13 March 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
KLKonstantinos Lontos
Konstantinos Lontos
YWYiyang Wang
Yiyang Wang
SJSupriya K Joshi
Supriya K Joshi
AFAndrew T Frisch
Andrew T Frisch
MWMcLane J Watson
McLane J Watson
GDGreg M Delgoffe
Greg M Delgoffe
Background: Cellular immunotherapies for cancer represent a means by which a patient’s immune system can be augmented with high numbers of tumor-specific T cells. Chimeric antigen receptor (CAR) therapy involves genetic engineering to ‘redirect’ peripheral T cells to tumor targets, showing remarkable potency in blood cancers. However, due to several resistance mechanisms, CAR-T cell therapies remain ineffective in solid tumors. We and others have shown the tumor microenvironment harbors a distinct metabolic landscape that produces a barrier to immune cell function. Further, altered differentiation of T cells within tumors induces defects in mitochondrial biogenesis, resulting in severe cell-intrinsic metabolic deficiencies. While we and others have shown murine T cell receptor (TCR)-transgenic cells can be improved through enhanced mitochondrial biogenesis, we sought to determine whether human CAR-T cells could be enabled through a metabolic reprogramming approach. Materials and methods: Anti-EGFR CAR-T cells were infused in NSG mice which bore A549 tumors. The tumor infiltrating lymphocytes were analyzed for exhaustion and metabolic deficiencies. Lentiviruses carrying PPAR-gamma coactivator 1α (PGC-1α), PGC-1αS571A and NT-PGC-1α constructs were used to co-transduce T cells with anti-EGFR CAR lentiviruses. We performed metabolic analysis via flow cytometry and Seahorse analysis in vitro as well as RNA sequencing. Finally, we treated therapeutically A549-carrying NSG mice with either PGC-1α or NT-PGC-1α anti-EGFR CAR-T cells. We also analyzed the differences in the tumor-infiltrating CAR-T cells when PGC-1α is co-expressed. Results: Here, in this study, we show that an inhibition resistant, engineered version of PGC-1α, can metabolically reprogram human CAR-T cells. Transcriptomic profiling of PGC-1α-transduced CAR-T cells showed this approach effectively induced mitochondrial biogenesis, but also upregulated programs associated with effector functions. Treatment of immunodeficient animals bearing human solid tumors with these cells resulted in substantially improved in vivo efficacy. In contrast, a truncated version of PGC-1α, NT-PGC-1α, did not improve the in vivo outcomes. Conclusions: Our data further support a role for metabolic reprogramming in immunomodulatory treatments and highlight the utility of genes like PGC-1α as attractive candidates to include in cargo along with chimeric receptors or TCRs for cell therapy of solid tumors.